David Butler, Ph.D., vice president of chemistry at Korro Bio, brings over 20 years of oligonucleotide and small molecule chemistry experience in the biotech industry.
Dave was previously vice president of medicinal chemistry at Wave Life Sciences where he led a team focused on stereopure phosphoramidite development, structural biology, and chemistry R&D across a broad range of therapeutic oligonucleotide modalities including RNase H, RNAi, and splice modulation.
Prior to Wave, Dave was a member of the medicinal chemistry team at Alnylam, where he worked on early siRNA delivery and cationic lipid technology, including the ONPATTRO® formulation.
Dave holds a B.Sc. (Hons) and Ph.D. in chemistry from the University of St. Andrews in Scotland.